Biopharmaceutical Company
Appears in 1 story
First commercial product sales achieved; patients receiving treatment nationwide
For decades, patients with transplant-associated thrombotic microangiopathy (TA-TMA) after stem cell transplants faced no FDA-approved treatment—mortality rates reached 80-90% for severe cases. In December 2025, the FDA approved Yartemlea, the first therapy for TA-TMA.
Updated May 23
No stories match your search
Try a different keyword
How would you like to describe your experience with the app today?
